

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robert John Watson, Andrew Douglas Baxter, Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter

Serial No. : 10/236,637

Filed : September 6, 2002

For : Hydroxamic and Carboxylic Acid Derivatives

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, the applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 10/236,637, filed September 6, 2002; and


U.S. Serial No. 09/855,978, filed May 15, 2001.

The subject application claims the benefit under 35 USC §120 of the filing date of the above referenced applications U.S. Serial No. 10/236,637 and 09/855,978. The applicants respectfully request that the references submitted in the Information Disclosure Statements in the parent applications, as well as any references cited during prosecution thereof, be made of record in the subject application. As copies of the references filed in the parent applications, and cited on the attached form PTO-1449, can be found in the parent casefiles, copies of those references are not provided herewith.

It is respectfully requested that the references cited in the above-noted parent application be considered in the examination of the subject application and their consideration be made of record.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

A handwritten signature in black ink that reads "David Saliwanchik". The signature is written in a cursive, flowing style.

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosure: Form PTO-1449

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not yet assigned
				Filing Date	March 17, 2004
				First Named Inventor	Duncan Batty
				Art Unit	1625
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	GJE-244D2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3				
	U4				
	U5				
	U6				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	WO	0012477	08/27/99	British Biotech Pharmaceuticals Limited	
	F2	WO	0012478	08/25/99	Zeneca Limited	
	F3	WO	9805635	08/07/97	Chiroscience Limited	
	F4	WO	9924399	11/12/98	Darwin Discovery Limited	
	F5	WO	9724117	01/02/97	Rhone-Poulenc Rorer Pharmaceuticals Inc.	
	F6	EP	0780386	12/10/96	F. Hoffmann-La Roche AG	
	F7					
	F8					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Not yet assigned
		Filing Date	March 17, 2004
		First Named Inventor	Duncan Batty
		Group Art Unit	1625
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	GJE-244D2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	Caplus English Abstract DN 120:323955, Bracher franz <i>et al.</i> , 1994, Vol. 327 (2).	
	R2	Caplus English Abstract DN 132:334370, J. Org. Chem., 2000, Vol. 65 (8).	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.